NCT05138822 - Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

December 3, 2024

Study Completion Date

December 3, 2024

Conditions

Uncomplicated Urinary Tract InfectionsUrinary Tract Infections

Interventions

DRUG

GSK3882347

GSK3882347 will be administered on each dosing day.

DRUG

Nitrofurantoin

Nitrofurantoin will be administered on each dosing day.

DRUG

Placebo

Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.

Trial Locations (15)

10456

GSK Investigational Site, The Bronx

15478

GSK Investigational Site, Smithfield

33157

GSK Investigational Site, Palmetto Bay

33166

GSK Investigational Site, Doral

33172

GSK Investigational Site, Sweetwater

33186

GSK Investigational Site, Miami

36207

GSK Investigational Site, Anniston

60643

GSK Investigational Site, Chicago

75230

GSK Investigational Site, Dallas

77061

GSK Investigational Site, Houston

77459

GSK Investigational Site, Missouri City

78705

GSK Investigational Site, Austin

90717

GSK Investigational Site, Lomita

95350-5365

GSK Investigational Site, Modesto

33016-1507

GSK Investigational Site, Miami Lakes